Business
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain Cash, cash equivalents and marketable securities of $1.3
About this update from Xenon Pharmaceuticals Inc.
[{"type":"image","alt":"Xenon Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Xenon Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s7o.0OXnOJy5uOTuo0NkvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b","width":250,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 ","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain ","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $1.3 billion extends cash runway into 2029","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call at 4:30 pm ET today","length":35,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":571,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.","length":400,"tagName":"p"},{"type":"text","content":"“In the first quarter of 2026, we announced positive results from our X-TOLE2 study, which exceeded expectations and reinforced azetukalner’s significant potential to provide a new therapeutic option for FOS patients with uncontrolled seizures. The strong X-TOLE2 results have paved the way for us to submit an NDA to the FDA in the third quarter of 2026 and our commercial preparedness act...